|
P-cadherin
| |
---|
Variable
|
Low
|
High
|
P-value
|
---|
Age, mean ± SD (years)
|
55.8 ± 11.5
|
55.7 ± 12.9
|
.428
|
PS (no.)
| | |
.627
|
0
|
52
|
67
| |
1
|
11
|
20
| |
2 or 3
|
4
|
8
| |
CA125 a(no.)
| | |
.262
|
≤136
|
37
|
42
| |
> 136
|
30
|
51
| |
NA
|
0
|
2
| |
Stage b(FIGO2014) (no.)
| | |
.0024*
|
Stage I/II
|
46
|
42
| |
Stage III/IV
|
21
|
53
| |
Peritoneal dissemination (no.)
| | |
2.7e-5*
|
Positive
|
18
|
58
| |
Negative
|
49
|
37
| |
Lymph node metastasis b(no.)
| | |
.823
|
Positive
|
9
|
15
| |
Negative
|
58
|
80
| |
Distant site metastasis (no.)
| | |
.048*
|
Positive
|
1
|
9
| |
Negative
|
65
|
86
| |
Histologic typeb (no.)
| | |
1.37e-10*
|
Clear cell
|
30
|
4
| |
Endometrioid
|
9
|
21
| |
Mucinous
|
12
|
11
| |
Serous
|
16
|
59
| |
- Clinicopathological characteristics of the 162 patients in association with P-cadherin expression
- *P < 0.05. aCutoff value as the median value. bPathological diagnosis. NA not available